May 14, 2026 08:31AM
Apr 2, 2026 08:31AM
Mar 18, 2026 05:00PM
Feb 19, 2026 07:30AM
Feb 19, 2026 07:30AM
Sep 8, 2025 07:01AM
Sep 8, 2025 07:00AM Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled
Jul 31, 2025 09:30AM
Jul 28, 2025 07:00AM
Jul 28, 2025 07:00AM
Jul 15, 2025 04:30PM
Jul 14, 2025 08:31AM
Jun 18, 2025 07:02AM
Jun 18, 2025 07:00AM Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study
Jun 11, 2025 04:30PM
May 22, 2025 08:31AM
May 12, 2025 08:31AM
Mar 19, 2025 07:04AM
Mar 19, 2025 07:00AM
Mar 10, 2025 08:31AM
Mar 6, 2025 08:31AM Biodexa Pharmaceuticals (BDRX) Appoints Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP
Feb 12, 2025 07:30AM
Feb 10, 2025 08:30AM
Jan 22, 2025 08:31AM
Nov 21, 2024 07:35AM
Nov 12, 2024 08:49AM
Oct 17, 2024 07:34AM
Oct 17, 2024 07:30AM Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer
Oct 15, 2024 04:15PM
Oct 4, 2024 08:30AM
Sep 19, 2024 04:30PM
Sep 16, 2024 08:32AM
Aug 12, 2024 04:40PM
Jul 19, 2024 08:31AM
Jul 11, 2024 08:32AM Biodexa Pharmaceuticals (BDRX) Reports Positive Results Of Phase 2 Trial Of eRapa
Jul 11, 2024 08:30AM

397,245 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All